Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg

被引:35
作者
Jindal, Ankur [1 ]
Bhardwaj, Ankit [2 ]
Kumar, Guresh [3 ]
Sarin, Shiv Kumar [1 ]
机构
[1] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India
[2] Inst Liver & Biliary Sci, Dept Epidemiol & Clin Res, New Delhi, India
[3] Inst Liver & Biliary Sci, Dept Biostat, New Delhi, India
关键词
PORTAL-HYPERTENSION; BETA-BLOCKERS; LIVER; DEFINITION; DIAGNOSIS; VARICES; RISK;
D O I
10.14309/ajg.0000000000000653
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Hepatic venous pressure gradient (HVPG) of >= 10 mm Hg predicts clinical decompensation (CD) in compensated cirrhosis. A proportion of cirrhotic patients at presentation have high HVPG (>= 20 mm Hg) and are compensated. The natural history, spectrum of CD, and mortality in this group is largely unknown. METHODS: Consecutive compensated cirrhotic patients with HVPG >= 6 mm Hg (n = 741) were followed up for 3-6 months for the development of any CD. Patients were classified based on the baseline HVPG (6 to <12 mm Hg [low HVPG, Gr.A, n = 163], 12 to <20 mm Hg [intermediate HVPG, Gr.B, n = 437] and >= 20 mm Hg [high HVPG, Gr.C, n = 141]). We analyzed the predictors of first CD, HVPG response to carvedilol, and mortality in these groups. RESULTS: CD developed in 217 (29.3%) patients during a mean follow-up of 1.6 +/- 0.4 years, and those who developed CD had higher baseline HVPG (17.02 +/- 4.79 vs 14.28 +/- 4.86;P< 0.001). First CD was seen earlier (1.3 +/- 0.7 years vs 1.5 +/- 0.6 years and 1.6 +/- 0.5 years,P= 0.02) and more frequently (44.7% vs 11% and 31.1%,P< 0.01) in high HVPG groups compared with low and intermediate HVPG groups, with higher mortality rates. Patients in the high HVPG group compared with the low HVPG group more often had NASH-cirrhosis (35.5% vs 19.6%;P0.001), higher liver stiffness values (45.06 +/- 20.46 vs 20.09 +/- 5.47 kPa,P< 0.001), and lower platelet counts (113.37 +/- 72.57 vs 151.7 +/- 87.30/cmm,P< 0.001). Patients with HVPG >= 12 mm Hg received carvedilol, and a repeat HVPG performed in a proportion after 9.3 +/- 2.4 months showed response (>= 20% reduction in HVPG or <12 mm Hg) in 31.6% patients (Gr. B, 44.9% > Gr. C, 22.2%,P< 0.05). Baseline HVPG (HVPG >= 12 to <20 mm Hg [Hazard ratio: 2.73] and HVPG >= 20 mm Hg [Hazard ratio: 4.48],P< 0.001) independently predicted CD. DISCUSSION: HVPG >= 20 mm Hg in patients with compensated cirrhosis independently predicts early and more frequent CD and poor outcomes. These patients should be labeled as "high-risk compensated cirrhosis," and early and effective interventions to reduce portal pressure should be initiated to improve long-term outcomes.
引用
收藏
页码:1624 / 1633
页数:10
相关论文
共 23 条
[1]   Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension [J].
Berzigotti, Annalisa ;
Rossi, Valentina ;
Tiani, Carolina ;
Pierpaoli, Lucia ;
Zappoli, Paola ;
Riili, Anna ;
Serra, Carla ;
Andreone, Pietro ;
Morelli, Maria Cristina ;
Golfieri, Rita ;
Rossi, Cristina ;
Magalotti, Donatella ;
Zoli, Marco .
JOURNAL OF GASTROENTEROLOGY, 2011, 46 (05) :687-695
[2]   Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial [J].
Bhardwaj, Ankit ;
Kedarisetty, Chandan Kumar ;
Vashishtha, Chitranshu ;
Bhadoria, Ajeet Singh ;
Jindal, Ankur ;
Kumar, Guresh ;
Choudhary, Ashok ;
Shasthry, S. M. ;
Maiwall, Rakhi ;
Kumar, Manoj ;
Bhatia, Vikram ;
Sarin, Shiv Kumar .
GUT, 2017, 66 (10) :1838-1843
[3]   REDUCTION OF THE INCREASED PORTAL VASCULAR-RESISTANCE OF THE ISOLATED PERFUSED CIRRHOTIC RAT-LIVER BY VASODILATORS [J].
BHATHAL, PS ;
GROSSMAN, HJ .
JOURNAL OF HEPATOLOGY, 1985, 1 (04) :325-337
[4]   The portal hypertension syndrome: etiology, classification, relevance, and animal models [J].
Bosch, Jaime ;
Iwakiri, Yasuko .
HEPATOLOGY INTERNATIONAL, 2018, 12 :S1-S10
[5]   The clinical use of HVPG measurements in chronic liver disease [J].
Bosch, Jaime ;
Abraldes, Juan G. ;
Berzigotti, Annalisa ;
Carlos Garcia-Pagan, Juan .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (10) :573-582
[6]   Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies [J].
D'Amico, G ;
Garcia-Tsao, G ;
Pagliaro, L .
JOURNAL OF HEPATOLOGY, 2006, 44 (01) :217-231
[8]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.jhep.2011.12.001, 10.1016/j.ejca.2011.12.021]
[9]   Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 [J].
Ferenci, P ;
Lockwood, A ;
Mullen, K ;
Tarter, R ;
Weissenborn, K ;
Blei, AT .
HEPATOLOGY, 2002, 35 (03) :716-721
[10]   Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases [J].
Garcia-Tsao, Guadalupe ;
Abraldes, Juan G. ;
Berzigotti, Annalisa ;
Bosch, Jaime .
HEPATOLOGY, 2017, 65 (01) :310-335